Immunotherapy in Prostate Cancer

被引：1
|
作者：
Bolat, Deniz [1 ,3 ]
Haydaroyu, Ayfer [2 ,3 ]
机构：
[1] Univ Hlth Sci, Izmir Bozyaka Training & Res Hosp, Clin Urol, Izmir, Turkey
[2] Ege Univ, Dept Radiat Oncol, Fac Med, Izmir, Turkey
[3] Ege Univ, Inst Hlth Sci, Dept Basic Oncol, Izmir, Turkey
来源：
UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY | 2019年 / 18卷 / 02期
关键词：
Prostate cancer; immunotherapy; vaccine; checkpoint blockers; survival; PHASE-III TRIAL; SIPULEUCEL-T; ANDROGEN DEPRIVATION; CTLA-4; BLOCKADE; DOSE-ESCALATION; PD-1; DOUBLE-BLIND; SURVIVAL; VACCINE; CHEMOTHERAPY;
D O I：
10.4274/uob.galenos.2018.1142
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In recent years, immunotherapy has become an important treatment alternative in the treatment of many cancers. Research on immunotherapy in prostate cancer has been accelerated by obtaining Food and Drug Administration (FDA) approval of sipuleucel-T for asymptomatic or minimal symptomatic metastatic castration-resistant prostate cancer (CRPC). Despite all these developments, the patients in whom these agents should be used, sequential use and combination strategies remain unclear. In this review, mechanisms of action and survival outcomes of different immunotherapeutic agents and therapeutic cancer vaccines in mCRPC are discussed.
引用
收藏
页码：67 / 72
页数：6
相关论文
共 50 条
  • [41] The immunotherapy of prostate and bladder cancer
    Totterman, TH
    Loskog, A
    Essand, M
    BJU INTERNATIONAL, 2005, 96 (05) : 728 - 735
  • [42] Combination Immunotherapy in Prostate Cancer
    Baxevanis, Constantin N.
    Goulielmaki, Maria
    Gritzapis, Angelos D.
    Fortis, Sotirios P.
    CANCERS, 2022, 14 (24)
  • [43] Immunotherapy for lethal prostate cancer
    Pasquale Rescigno
    Johann S. de Bono
    Nature Reviews Urology, 2019, 16 : 69 - 70
  • [44] Adjuvant immunotherapy of prostate cancer for stage III prostate cancer
    Macalalag, Eufemio V.
    Macalalag, Michael L.
    Perez-Macalalag, Eden P.
    JOURNAL OF UROLOGY, 2007, 177 (04): : 202 - 202
  • [45] Immunotherapy for prostate cancer: is prostate an immune responsive tumor?
    Slovin, Susan F.
    CURRENT OPINION IN UROLOGY, 2016, 26 (06) : 529 - 534
  • [46] Immunotherapy in castration resistant prostate cancer
    Minana Lopez, Bernardino
    Villacampa Auba, Felipe
    de Fata Chilton, Fernando Ramon
    Ancizu Markert, Francisco Javier
    Garcia Cortes, Angel
    Domenech Lopez, Pablo
    Chiva San Roman, Santiago
    Veils Campillo, Jose Maria
    Diez-Caballero Alonso, Fernando
    Robles Garcia, Jose Enrique
    Roseii Costa, David
    Pascual Piedrola, Juan Ignacio
    ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (08): : 685 - 695
  • [47] Gene therapy and immunotherapy for prostate cancer
    Fiedler, U
    Wirth, MP
    UROLOGE A, 2001, 40 (03): : 207 - 216
  • [48] Immunology and immunotherapy approaches for prostate cancer
    E Elkord
    Prostate Cancer and Prostatic Diseases, 2007, 10 : 224 - 236
  • [49] Prostate cancer as a model for tumour immunotherapy
    Charles G. Drake
    Nature Reviews Immunology, 2010, 10 : 580 - 593
  • [50] Immunotherapy of Prostate Cancer: Facts and Hopes
    Bilusic, Marijo
    Madan, Ravi A.
    Gulley, James L.
    CLINICAL CANCER RESEARCH, 2017, 23 (22) : 6764 - 6770
12345